Keytruda (pembrolizumab)

pCPA File Number: 22011
Negotiation Status:
Under consideration for negotiation
For the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
Merck Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable